Given that many here can evaluate biotech oncology-related companies, the results of this conference are likely to be of interest to others on the board.
Although it is a blood cancer conference, the new science being presented in immuno-oncology is applicable to solid tumors and is therefore directly related to the future of NWBO.
There is a possibility that a competitor to NWBO can emerge from the companies presenting results. Might be of interest as well.
Some here may want to invest in some of the companies presenting. That doesn’t mean it is necessary to sell NWBO — it is possible to bet on more than one horse in a race. Going “all in” on one “sure” bet is, in general, a sure path to the poor house.
News 
Market Data 
Discover 
